Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07836101 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

Name: Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events — clinical trial record (NCT07836101)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IRIS

StatusNot Yet Recruiting

PhasePhase 2

SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Started2026-10

View on ClinicalTrials.gov ↗

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

135 trials monitored

See 15 trials at risk

The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria

Trial Details

NCT Number	NCT07836101
Lead Sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Collaborators: Sanofi-Regeneron, Bristol-Myers Squibb
Conditions	Any Advanced Solid Tumors
Enrollment	41 participants
Start Date	2026-10
Primary Completion	2029-08 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-23